What Are Continuous Glucose Monitors?

Continuous Glucose Monitors are compact medical devices that measure glucose levels in the interstitial fluid—the fluid that surrounds cells just beneath the skin. Unlike traditional blood glucose meters that require a fingerstick blood sample for each reading, CGMs automatically record glucose levels every few minutes, 24 hours a day. This continuous stream of data provides a dynamic picture of glucose trends, including rapid spikes after meals, overnight lows, and how physical activity affects levels.

The first CGM systems were bulky and required frequent calibration, but modern devices have become smaller, more accurate, and easier to use. Today, CGMs are often prescribed for people with type 1 diabetes, but their use is expanding to type 2 diabetes, gestational diabetes, and even non-diabetic applications like athletic performance monitoring. The core value proposition remains the same: real-time visibility into glucose dynamics that fingerstick checks simply cannot provide.

The evolution of CGM technology has also transformed clinical practice. Endocrinologists and diabetes educators now rely on CGM data to make medication adjustments, identify problematic patterns, and counsel patients on lifestyle modifications. The ability to see glucose variability—not just average levels—has shifted the focus from HbA1c alone to time-in-range as a more actionable metric.

How Do CGMs Work?

A CGM system consists of three main components: a sensor, a transmitter, and a receiver or smartphone app. The sensor is a thin, flexible filament inserted just under the skin—usually on the abdomen or upper arm. It uses an enzyme-based electrochemical reaction to measure glucose concentration in the interstitial fluid every one to five minutes. The transmitter, attached to the sensor, wirelessly sends these readings to a display device. The receiver or app processes the data, showing current glucose levels, trend arrows (pointing up, down, or steady), and graphs of glucose history.

The Components of a CGM System

  • Sensor: A disposable or semi-disposable filament inserted subcutaneously. It has a tiny electrode coated with glucose oxidase, which generates an electrical current proportional to glucose concentration. Sensors typically last from 7 to 14 days, depending on the brand. The sensor’s enzyme layer must remain stable and biocompatible; manufacturers use specialized polymers to minimize inflammation and signal drift over the wear period.
  • Transmitter: A small, often reusable device that snaps onto the sensor housing. It powers the sensor via a small battery and transmits data via Bluetooth or proprietary radio frequency to the receiver. Some transmitters are rechargeable and last for several months, while others are integrated into the sensor and disposed of after use. The transmitter communicates with the receiver at regular intervals, and its signal range typically extends 20–30 feet.
  • Receiver/App: Today, most CGMs pair directly with a smartphone app that displays readings, trend graphs, and alerts. Some also come with a dedicated handheld receiver for individuals who prefer not to use a phone. The app can share data with healthcare providers and caregivers, and many offer customizable thresholds for high and low glucose alerts. Advanced apps integrate with cloud-based platforms that allow clinics to review patient data remotely.

An important nuance is the physiological lag time. Interstitial glucose levels trail blood glucose by about 5–15 minutes. This means that during rapid changes—like after a meal or during exercise—the CGM reading may not exactly match a fingerstick measurement. Manufacturers have improved algorithms with smoothing and calibration techniques to minimize this discrepancy, but it remains a consideration when making time-sensitive treatment decisions. Some CGMs also require periodic calibration with fingerstick blood glucose readings to maintain accuracy, while newer models are factory-calibrated and do not need user calibrations. Factory-calibrated sensors use a one-time, manufacturer-performed calibration curve for the entire lot, reducing user error and improving convenience.

Benefits of Continuous Glucose Monitoring

Extensive clinical evidence supports the advantages of CGM use. The landmark DIaMonD and REPLACE-BG studies demonstrated that CGM use significantly reduces HbA1c levels and decreases the time spent in hypoglycemia (dangerously low blood sugar). A 2020 meta-analysis published in BMJ Open Diabetes Research & Care found that CGM users experienced an average HbA1c reduction of 0.3–0.6% compared to those using self-monitoring of blood glucose alone. More recent trials have focused on time-in-range as a primary endpoint, with improvements of 15–20% in CGM users.

  • Real-Time Data and Alerts: CGMs alert users when glucose is rising or falling too quickly, enabling early intervention before severe highs or lows occur. Hypoglycemia alerts can be set to sound when glucose drops below a user-defined threshold (e.g., 70 mg/dL), and predictive alerts can warn 20–30 minutes before a low is expected.
  • Trend Analysis: The ability to see glucose patterns—such as dawn phenomenon, postprandial spikes, or exercise-induced dips—helps fine-tune insulin dosing, meal timing, and activity schedules. Ambulatory glucose profile (AGP) reports are now standard output from CGM systems, offering a standardized 14-day view of glucose metrics.
  • Reduced Finger Pricks: While some fingersticks are still needed for calibration or verification, the frequency is dramatically reduced—often to zero or a few per week. This alone can reduce the burden of diabetes management and improve adherence.
  • Improved Glycemic Control: The constant feedback loop encourages behavioral changes and medication adjustments, leading to better blood glucose management and fewer diabetic complications over time. Studies show that even patients with poor baseline control achieve significant HbA1c reductions with consistent CGM use.
  • Greater Quality of Life: Freedom from constant finger pricking, reduced anxiety about unknown glucose levels, and better sleep (thanks to overnight alerts) contribute to overall well-being. Many users report a sense of empowerment and confidence in managing their condition.

For individuals using insulin pumps, CGMs can be integrated into hybrid closed-loop systems—often called "artificial pancreas" systems—that automatically adjust insulin delivery based on sensor readings. These systems have been shown to improve time-in-range (glucose between 70–180 mg/dL) by up to 10–15% compared with pump + fingerstick alone. The integration also reduces the burden of manual insulin adjustments and helps prevent both hyperglycemia and hypoglycemia, particularly overnight.

Challenges and Limitations

Despite their transformative potential, CGMs come with challenges that must be acknowledged. Understanding these limitations helps users and clinicians set realistic expectations and address issues proactively.

  • Cost and Insurance Coverage: CGMs can be expensive. In the United States, out-of-pocket costs range from $1,500–$4,000 per year without insurance, and while many private insurers and Medicare cover CGMs for type 1 and insulin-using type 2 patients, coverage for non-insulin users varies widely. The CDC provides guidance on CGM coverage and a list of Medicare criteria. In many other countries, public health systems reimburse CGMs only for select patient groups, leading to inequities in access.
  • Accuracy Concerns: Although modern CGMs have Mean Absolute Relative Difference (MARD) values as low as 8–10% (approaching fingerstick accuracy), readings can still be affected by sensor placement, dehydration, certain medications (e.g., acetaminophen at high doses), or pressure on the sensor (compression lows). Users must be educated about these factors and instructed to confirm with a fingerstick when symptoms do not match readings.
  • Skin Irritation and Adhesion Issues: Adhesives can cause redness, itching, or rashes, especially with long-term wear. Some users develop allergies to the adhesive or the sensor material. Manufacturers have introduced hypoallergenic adhesives and skin barriers, but the problem persists for a subset of users. Rotating sensor sites and using protective films can help.
  • Data Overload: The continuous stream of information can be overwhelming for some users, leading to "alarm fatigue" or obsessive checking. Educational support is essential to help users interpret trends without unnecessary stress. Clinicians should encourage users to focus on patterns rather than individual readings and to customize alert settings to reduce nuisance alarms.
  • Calibration Requirements: Older or budget CGM models still require regular fingerstick calibrations, adding steps and potential for user error. Factory-calibrated sensors eliminate this but may not be suitable for all patients, particularly those with extreme glucose variability or unusual physiology that does not match the calibration curve.
  • Interference and Compatibility: Some systems may have interference from substances like acetaminophen, uric acid, or ascorbic acid. Additionally, certain CGM models are proprietary and only work with specific pump systems, limiting user choice and driving vendor lock-in. Interoperability standards are being developed by the FDA to address this.

Who Should Use a CGM?

Continuous Glucose Monitors are recommended for a broad range of individuals, though clinical guidelines vary. Selection should be individualized based on diabetes type, treatment regimen, hypoglycemia risk, psychological readiness, and goals.

  • Type 1 Diabetes Patients: The American Diabetes Association (ADA) recommends CGMs for all adults with type 1 diabetes who are willing and able to use them. Studies show near-universal benefit in reducing hypoglycemia and improving HbA1c regardless of age or prior control level. Children as young as age 2 can use CGMs, and the devices have been shown to reduce parental anxiety and improve family quality of life.
  • Type 2 Diabetes Patients: For those on intensive insulin therapy (multiple daily injections or pump), CGMs are strongly recommended. For non-insulin users, the evidence is growing: a 2022 study in Diabetes Care found that CGM use in type 2 patients not on insulin led to significant reductions in HbA1c (0.4%) without increasing hypoglycemia. The ADA now considers CGMs for type 2 patients on basal insulin alone or even on oral agents if they are not meeting glycemic targets.
  • Pregnant Women: Gestational diabetes and pre-existing diabetes during pregnancy require tight glucose control to reduce risks to mother and baby. CGMs provide the detailed trend data needed to manage postprandial spikes and overnight lows safely. Several studies have shown that CGM use in pregnancy improves neonatal outcomes, including reduced rates of large-for-gestational-age infants and fewer admissions to the neonatal intensive care unit.
  • Individuals with Hypoglycemia Unawareness: Those who cannot feel their blood sugar dropping (a dangerous condition common in long-standing diabetes) benefit enormously from CGM alerts that wake them up or prompt action. CGMs are considered a first-line intervention for hypoglycemia unawareness, and continuous use can restore some awareness over time.
  • Non-Diabetic Populations (Emerging): Athletes and biohackers increasingly use CGMs to understand how different foods and workouts affect their glucose, aiming to optimize performance and energy. However, this off-label use is not yet supported by strong outcome data and should be approached cautiously. Some experts caution that the devices can lead to unnecessary anxiety over normal glucose fluctuations in healthy individuals.

The three most widely used CGM systems in the United States and Europe are listed below. Each has distinct features, and the choice often depends on pump compatibility, sensor wear duration, and personal preference.

  • Dexcom G7 / G6: Known for best-in-class accuracy (MARD ~8–9%), 10-day sensor wear, no fingerstick calibrations required, and ability to share data with up to 10 followers via smartphone. The G7 is even smaller and warms up faster than the G6. System seamlessly integrates with Tandem insulin pumps and is anticipated to work with others in the future. Learn more at Dexcom.
  • Abbott Freestyle Libre 3: Features a 14-day sensor, the thinnest on the market, and a small transmitter that syncs directly with a smartphone app. Its MARD is around 9–10%. The Libre 3 is fully disposable and does not require fingerstick calibrations. It also offers optional real-time alarms when paired with a compatible smartphone. The system is not currently integrated with insulin pumps, though Abbott has announced future pump integration plans. See Abbott's site.
  • Medtronic Guardian 4: Works exclusively with Medtronic insulin pumps (e.g., 780G) as part of a hybrid closed-loop system. It requires calibration twice daily but integrates seamlessly with pump therapy. The Guardian 4 sensor lasts 7 days. Medtronic's latest system also includes a SmartGuard feature that automatically suspends insulin delivery when a low is predicted.

Choosing among these systems involves balancing sensor wear time, accuracy, cost, and compatibility. Patients who use an insulin pump should consider whether they want a closed-loop system; those who rely on injections may prefer a simple standalone CGM like the Libre. It is also important to consider the user-friendliness of the smartphone app and follow-up data access for clinicians.

The Role of CGMs in Pregnancy and Gestational Diabetes

Pregnancy induces significant insulin resistance, making glucose control particularly challenging. CGMs have proven invaluable by providing the granular data needed to adjust meal timing, exercise, and insulin doses. A 2017 multicenter randomized trial (CONCEPTT) demonstrated that pregnant women with type 1 diabetes who used CGMs had significantly improved neonatal outcomes, including fewer large-for-gestational-age babies and fewer episodes of neonatal hypoglycemia. The trial also showed a modest reduction in maternal HbA1c and more time spent in the target glucose range.

For gestational diabetes, pilot studies suggest CGMs can help identify postprandial glucose spikes that might otherwise go unnoticed with traditional self-monitoring. The ability to see overnight trends is especially important, as nocturnal hypoglycemia can be dangerous for both mother and fetus. Some clinicians now advocate for short-term CGM use in women with gestational diabetes who are not meeting targets on diet or oral medications, as the data can guide earlier initiation of insulin therapy. However, larger randomized trials are needed before universal recommendations can be made.

Practical considerations during pregnancy include the possibility of sensor inaccuracy due to weight gain and edema, as well as the need for more frequent calibration (if using a system that requires it). Expectant mothers should work closely with their diabetes care team to set appropriate target ranges, which are generally tighter than in the non-pregnant state.

The Future of Glucose Monitoring

The pace of innovation in glucose monitoring continues to accelerate. The next generation of CGMs aims to be non-invasive, longer-lasting, and smarter. Regulatory bodies like the FDA are also adapting to facilitate faster approval of interoperable devices.

Emerging Technologies

  • Non-Invasive Sensors: Several companies are developing wearables that measure glucose through the skin using optical, thermal, or electromagnetic methods—no filament insertion required. For example, Know Labs is using radiofrequency spectroscopy, and DiaMonTech uses mid-infrared laser absorption. While promising, these devices are still in clinical trials and have yet to match the accuracy of current invasive sensors. A major hurdle is the signal-to-noise ratio, as the skin and interstitial fluid interfere with measurements.
  • Artificial Intelligence and Predictive Alerts: Machine learning algorithms can now predict glucose trends 30–60 minutes in advance, allowing users to prevent hyper- or hypoglycemia before it occurs. The latest Medtronic and Dexcom systems already incorporate predictive alerts, and future versions may suggest specific insulin doses or carbohydrate corrections. These AI models are trained on large datasets from thousands of patients, improving their generalizability.
  • Integration with Smartwatches and Fitness Trackers: Direct sensor–to–watch communication is becoming standard. The Dexcom G7 can display glucose readings on an Apple Watch; similar integrations are expected for Wear OS. Future CGMs might also use data from heart rate, steps, and sleep to further refine predictions. Some fitness-focused wearables, like the Fitbit or Garmin watches, are exploring native CGM data display, which would allow users to see glucose alongside other health metrics.
  • Longer Wear Times and Biocompatible Sensors: Researchers are developing sensors that last 14–30 days or even months, reducing the burden of frequent replacements. Bioabsorbable or fully implantable sensors that degrade safely in the body after a set period are also in early-stage development. Such sensors would eliminate the need for frequent insertion, but challenges remain in maintaining accuracy over extended periods and ensuring safe resorption.
  • Closed-Loop Systems Becoming Mainstream: Already, systems like the Medtronic 780G and Tandem t:slim X2 with Control-IQ automatically adjust basal insulin based on CGM data. Future iterations will incorporate dual-hormone delivery (insulin + glucagon), further automating management and reducing user burden. Dual-hormone systems have shown promise in clinical trials for better glucose control and fewer hypoglycemic events, though they require a second pump reservoir and additional cannula insertion.

The U.S. Food and Drug Administration has recognized the potential of these technologies and is working to streamline approvals for interoperable CGMs—sensors that can pair with any compatible insulin pump or app. This interoperability will drive competition and lower costs. The FDA's CGM standards page provides details on current regulatory frameworks, including the "iCGM" designation for interoperable devices. As these standards mature, patients will gain more flexibility to choose best-in-class components.

Conclusion

Real-time glucose monitoring through Continuous Glucose Monitors has fundamentally changed the way people manage diabetes. By providing a continuous, accurate picture of glucose dynamics, CGMs empower individuals to make smarter decisions every day—reducing dangerous highs and lows, improving overall glucose control, and enhancing quality of life. While challenges like cost and skin irritation remain, ongoing technological breakthroughs—non-invasive sensors, AI-driven predictions, and tighter integration with insulin pumps—promise to make CGM technology even more accessible and effective in the years ahead. For anyone living with diabetes, the question is no longer if they should consider a CGM, but when—and with each new innovation, that answer becomes clearer.